Savara (SVRA) Income from Continuing Operations (2010 - 2026)
Savara's (SVRA) quarterly Income from Continuing Operations came in at 39854000.0 in Q1 2026, down 49.61% year-on-year from 79087507.9 in Q1 2025, and down 28.83% on a QoQ basis from 30935000.0 in Q4 2025.
Savara (SVRA) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Income from Continuing Operations data on file, last reported at 39854000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 49.61% year-over-year to 39854000.0 in Q1 2026; TTM through Mar 2026 was 132479000.0, a 22.48% decrease from a year earlier, with the FY2025 full-year figure at 266280000.0, down 26.49% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 39854000.0, down from 30935000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for SVRA reached as high as 8618000.0 in Q1 2022 and fell as low as 39854000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 21374176.47 across 5 years, with a median of 20346000.0 in 2024.
- Across the five-year window, Income from Continuing Operations rose 21.11% in 2022 and slumped 85.18% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 11274000.0 in 2022, then plunged by 58.9% to 17914000.0 in 2023, then sank by 78.31% to 31942000.0 in 2024, then increased by 3.15% to 30935000.0 in 2025, then slipped by 28.83% to 39854000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 39854000.0 in Q1 2026, 30935000.0 in Q4 2025, and 30132000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Savara | 1.24 Bn | 1.24 Bn | - | -39.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.85 Mn |
| Dec 31, 2025 | -30.94 Mn |
| Sep 30, 2025 | -30.13 Mn |
| Jun 30, 2025 | -31.56 Mn |
| Mar 31, 2025 | -26.64 Mn |
| Dec 31, 2024 | -31.94 Mn |
| Sep 30, 2024 | -26.06 Mn |
| Jun 30, 2024 | -23.52 Mn |
| Mar 31, 2024 | -20.35 Mn |
| Dec 31, 2023 | -17.91 Mn |
| Sep 30, 2023 | -18.44 Mn |
| Jun 30, 2023 | -12.70 Mn |
| Mar 31, 2023 | -12.56 Mn |
| Dec 31, 2022 | -11.27 Mn |
| Sep 30, 2022 | -10.96 Mn |
| Jun 30, 2022 | -9.90 Mn |
| Mar 31, 2022 | -8.62 Mn |
| Dec 31, 2021 | -11.18 Mn |
| Sep 30, 2021 | -10.08 Mn |
| Jun 30, 2021 | -10.54 Mn |